MX2023009520A - Compuesto de 4-aminoquinazolina. - Google Patents

Compuesto de 4-aminoquinazolina.

Info

Publication number
MX2023009520A
MX2023009520A MX2023009520A MX2023009520A MX2023009520A MX 2023009520 A MX2023009520 A MX 2023009520A MX 2023009520 A MX2023009520 A MX 2023009520A MX 2023009520 A MX2023009520 A MX 2023009520A MX 2023009520 A MX2023009520 A MX 2023009520A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
compounds
aminoquinazoline
present
useful
Prior art date
Application number
MX2023009520A
Other languages
English (en)
Spanish (es)
Inventor
Mitsuaki Okumura
Hiroki Fukudome
Tomoyoshi Imaizumi
Hisao Hamaguchi
Ikumi Kuriwaki
Sunao Imada
Hiroki Ishioka
Kazuyuki Kuramoto
Takeyuki Nagashima
Kenichi Kawaguchi
Ryo Sato
Yohei Seki
Takahiro Morikawa
Eiji Kawaminami
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2023009520A publication Critical patent/MX2023009520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023009520A 2021-02-15 2022-02-14 Compuesto de 4-aminoquinazolina. MX2023009520A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021021684 2021-02-15
PCT/JP2022/005583 WO2022173033A1 (ja) 2021-02-15 2022-02-14 4-アミノキナゾリン化合物

Publications (1)

Publication Number Publication Date
MX2023009520A true MX2023009520A (es) 2023-08-24

Family

ID=82838845

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009520A MX2023009520A (es) 2021-02-15 2022-02-14 Compuesto de 4-aminoquinazolina.

Country Status (12)

Country Link
US (1) US20240150366A1 (cg-RX-API-DMAC7.html)
EP (1) EP4293025B1 (cg-RX-API-DMAC7.html)
JP (1) JP7725511B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230145360A (cg-RX-API-DMAC7.html)
CN (1) CN116867788B (cg-RX-API-DMAC7.html)
AU (1) AU2022219651A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211110A1 (cg-RX-API-DMAC7.html)
ES (1) ES3054794T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023009520A (cg-RX-API-DMAC7.html)
PL (1) PL4293025T3 (cg-RX-API-DMAC7.html)
SA (1) SA523450286B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022173033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7629580B1 (ja) 2022-01-21 2025-02-13 ユーシノヴァ・ファーマシューティカルズ・リミテッド ベンゾピリミジン化合物及びその使用
CA3255513A1 (en) * 2022-03-11 2025-03-04 Astellas Pharma Inc. HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
EP4568674A1 (en) * 2022-08-12 2025-06-18 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
AU2023322690A1 (en) * 2022-08-12 2025-03-20 Astellas Pharma Inc. Anti cancer combinations comprising chemotherapy
WO2024188281A1 (zh) * 2023-03-13 2024-09-19 南京明德新药研发有限公司 含喹唑啉结构的化合物及其应用
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
CN114222743A (zh) * 2019-08-16 2022-03-22 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物,其制法与医药上的用途
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
EP4293025B1 (en) 2025-10-29
WO2022173033A1 (ja) 2022-08-18
PL4293025T3 (pl) 2026-02-16
JPWO2022173033A1 (cg-RX-API-DMAC7.html) 2022-08-18
SA523450286B1 (ar) 2024-06-12
EP4293025A1 (en) 2023-12-20
CA3211110A1 (en) 2022-08-18
JP7725511B2 (ja) 2025-08-19
KR20230145360A (ko) 2023-10-17
EP4293025A4 (en) 2025-02-26
US20240150366A1 (en) 2024-05-09
ES3054794T3 (en) 2026-02-06
EP4293025C0 (en) 2025-10-29
CN116867788B (zh) 2026-05-26
CN116867788A (zh) 2023-10-10
AU2022219651A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
CR20230404A (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
SA523450286B1 (ar) مركب 4-أمينو كوينازولين
GEAP202616866A (en) 2-azabicyclo[2.2.1]heptane kras inhibitors
MX2024007853A (es) Composicion farmaceutica que comprende un compuesto de quinazolina.
MX2025000772A (es) Compuesto heterociclico que actua sobre la proteina kras mutante g12d
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
MX2024011056A (es) Compuesto heterociclico para inducir la degradacion de la proteina kras mutante g12d.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2024000357A (es) Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
PH12022552739A1 (en) Fused tricyclic kras inhibitors
MX2025003821A (es) Compuestos con actividad contra tumores mutantes de kras
ZA202403388B (en) Small molecules for treatement of cancer
SG11201907038WA (en) Quinazoline compound
MX2023007192A (es) Inhibidores de prmt5.
WO2022221528A3 (en) Kras g12c inhibitors
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MA55145B1 (fr) Polythérapie incluant un inhibiteur de kras g12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
ZA202404648B (en) Azetidine and pyrrolidine parp1 inhibitors and uses thereof
MX2024013020A (es) Compuestos de heteroarilo para el tratamiento del dolor
ZA202203520B (en) [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors
CR20240514A (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
WO2025019819A3 (en) Small molecule protein degraders of kras g12d mutant
WO2019199667A3 (en) Pladienolide compounds and their use